Xcytrin (motexafin gadolinum) / AbbVie 
Welcome,         Profile    Billing    Logout  
 115 Diseases   2 Trials   2 Trials   57 News 
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Review, Journal:  Inhibition of the thioredoxin system for radiosensitization therapy of cancer. (Pubmed Central) -  Mar 18, 2024   
    Notable radiosensitizers, including gold nanoparticles (GNPs), gold triethylphosphine cyanide ([Au(SCN) (PEt3)]), auranofin, ceria nanoparticles (CONPs), curcumin and its derivatives, piperlongamide, indolequinone derivatives, micheliolide, motexafin gadolinium, and ethane selenide selenidazole derivatives (SeDs), are meticulously elucidated in terms of their applications in radiotherapy. In this review, the sensitization mechanisms and the current research progress of these radiosensitizers are discussed in detail, with the overall aim of providing valuable insights for the judicious application of Trx system inhibitors in the field of cancer radiosensitization therapy.
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Journal:  Lutetium texaphyrin: A photocatalyst that triggers pyroptosis via biomolecular photoredox catalysis. (Pubmed Central) -  Feb 25, 2024   
    The first control, gadolinium texaphyrin (MGd), is a weak photocatalyst but generates reactive oxygen species (ROS) efficiently...Even in the presence of a ROS scavenger, treating MDA-MB-231 cells with MLu at concentrations as low as 50 nM still allows for pyroptosis photo-activation. The present findings highlight how biomolecular photoredox catalysis could contribute to pyroptosis activation by mechanisms largely independent of ROS.
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Journal:  Myoglobin-loaded gadolinium nanotexaphyrins for oxygen synergy and imaging-guided radiosensitization therapy. (Pubmed Central) -  Oct 4, 2023   
    Gadolinium (Gd)-coordinated texaphyrin (Gd-Tex) is a promising radiosensitizer that entered clinical trials, but temporarily fails largely due to insufficient radiosensitization efficacy...In addition to Gd, the versatile Mb@Gd-NTs can also chelate Lu (Mb@Lu/Gd-NTs), enabling SPECT/MRI dual-modality imaging for accurately monitoring drug delivery in real-time. This "one-for-all" nanoplatform with the capability of chelating various trivalent metal ions exhibits broad clinical application prospects in imaging-guided radiosensitization therapy.
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Trial completion date, Trial primary completion date:  ACRIN6690: Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy (clinicaltrials.gov) -  Jul 7, 2023   
    P=N/A,  N=440, Active, not recruiting, 
    This "one-for-all" nanoplatform with the capability of chelating various trivalent metal ions exhibits broad clinical application prospects in imaging-guided radiosensitization therapy. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Journal:  Development of a Three-Dimensional Multi-Modal Perfusion-Thermal Electrode System for Complete Tumor Eradication. (Pubmed Central) -  Oct 15, 2022   
    Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 This new 3D, perfusion-thermal electrode system provided the evidence on the potential to enable simultaneous delivery of therapeutic agents and RF hyperthermia into the difficult-to-treat peritumoral zones, creating a new strategy to address the critical limitation, i.e., the high incidence of residual and recurrent tumor following thermal ablation of unresectable medium-to-large and irregular tumors.
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Trial completion date, Trial primary completion date:  Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer (clinicaltrials.gov) -  Oct 18, 2021   
    P=N/A,  N=30, Active, not recruiting, 
    This new 3D, perfusion-thermal electrode system provided the evidence on the potential to enable simultaneous delivery of therapeutic agents and RF hyperthermia into the difficult-to-treat peritumoral zones, creating a new strategy to address the critical limitation, i.e., the high incidence of residual and recurrent tumor following thermal ablation of unresectable medium-to-large and irregular tumors. Trial completion date: Dec 2021 --> Dec 2022 | Trial primary completion date: Dec 2020 --> Dec 2022
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Trial completion date, Trial primary completion date:  Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer (clinicaltrials.gov) -  Aug 25, 2020   
    P=N/A,  N=30, Active, not recruiting, 
    The drugs screened using our strategy may be effective candidates for treating patients with COVID-19. Trial completion date: Dec 2019 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Dec 2020
  • ||||||||||  oxaliplatin / Generic mfg., Xcytrin (motexafin gadolinum) / AbbVie
    Journal:  Oxaliplatin Pt(IV) prodrugs conjugated to gadolinium-texaphyrin as potential antitumor agents. (Pubmed Central) -  Jul 19, 2020   
    A combination of tumor localization, redox cycling, and reversible protein binding is invoked to explain the relatively increased tolerability and enhanced anticancer activity seen in vivo. On the basis of the present studies, we conclude that metallotexaphyrin-Pt conjugates may have substantial clinical potential as antitumor agents.
  • ||||||||||  doxorubicin hydrochloride / Generic mfg.
    Review, Journal:  Understanding of ROS-Inducing Strategy in Anticancer Therapy. (Pubmed Central) -  Jun 25, 2020   
    Our review will be helpful to improve the therapeutic effects of anticancer drugs by providing information about biological changes that occur in response to prooxidants. For future directions, there is still a need for pharmacogenomic studies on prooxidative agents as well as the molecular mechanisms underlying the effects of the prooxidants and/or antioxidant-inhibitor agents for effective anticancer therapy through selective killing of cancer cells.
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Journal:  CPS1 expression and its prognostic significance in lung adenocarcinoma. (Pubmed Central) -  May 2, 2020   
    Our work indicated that CPS1 is upregulated in LADC samples and that CPS1 might be used as a potential biomarker for the diagnostic and prognostic evaluation of LADC. Determining the detailed biological function of CPS1 in LADC tissues will provide promising and insightful information for our further study.
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Trial completion date, Trial primary completion date:  Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer (clinicaltrials.gov) -  Jul 5, 2019   
    P=N/A,  N=30, Active, not recruiting, 
    Determining the detailed biological function of CPS1 in LADC tissues will provide promising and insightful information for our further study. Trial completion date: Jan 2019 --> Dec 2019 | Trial primary completion date: Jan 2019 --> Dec 2019
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Enrollment closed, Trial primary completion date:  ACRIN6690: Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy (clinicaltrials.gov) -  Mar 20, 2017   
    P=N/A,  N=440, Active, not recruiting, 
    Trial primary completion date: Jan 2018 --> Jan 2019 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2022
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Phase classification, Trial primary completion date:  Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer (clinicaltrials.gov) -  Mar 20, 2017   
    P=N/A,  N=30, Active, not recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2015 --> Dec 2022 Phase classification: P1 --> P=N/A | Trial primary completion date: Jan 2015 --> Jan 2018
  • ||||||||||  Xcytrin (motexafin gadolinum) / AbbVie
    Trial termination:  Trial of Motexafin Gadolinium and Pemetrexed (Alimta (clinicaltrials.gov) -  Oct 23, 2013   
    P2,  N=74, Terminated, 
    Completed --> Terminated Completed --> Terminated